GHRP -6 5mg USA

The description

GHRP 6 is not an active fragment of growth hormone releasing hormone (GHRH). It is one of many synthetic met-enkephalin analogs that include non-naturally occurring D-amino acids that have been developed for their growth hormone release activity and are called growth hormone secretagogues. GHRP 6 is a true secretagogue of hGH. Which means that it stimulates the body's own secretion of hGH as explained in the study below. Human growth hormone has been shown in studies to promote lean body mass and reduce fatness. It is now known that these growth hormone-releasing peptides are distinct from GHRH and do not act on the GHRH receptor, but rather act on the secretagogue receptor for growth hormone, now renamed ghrelin receptor. It is for this reason (properties similar to Gherlin) patients treated with GHRP 6 experience of appetite stimulation. In therapy, GHRP 6 is used to stimulate growth hormone production while increasing body mass. Patients deficient in growth hormone and underweight would be ideal candidates for GHRP 6.
Clinical research

"The growth hormone releasing peptide (GHRP 6) stimulates phosphatidylinositol (PI) turnover in pituitary human somatotropic cells." - Lei T, Muckfelder B, Fahlbusch R, Adams EF.

Source: Department of Neurosurgery, University of Erlangen-Nürnberg, Germany.

Abstract: The growth hormone releasing peptide (GHRP 6) is a synthetic hexapeptide that specifically stimulates the secretion of growth hormone (GH) by pituitary somatotropes. The precise intracellular mechanism by which this is achieved has not been deciphered although it is known to involve protein kinase C (PKC) and Ca2 + but be independent of cAMP. We used human pituitary somatotropinoma cell cultures to demonstrate the potent effects of GHRP 6 on membrane turnover of phosphatidylinositol (PI), a second messenger system that leads to activation of PKC and mobilization of Ca2 + stores. intracellular. The incubation of somatotrophinoma cells with GHRP 6 led to a dose-dependent stimulation of the rate of PI turnover. The secretion of GH has been increased in parallel. The effects were discernible after only 15 minutes of incubation and peaked at 2 hours. PI turnover was stimulated by GHRP 6 in 8 of the 8 tumors examined, with effects ranging from 2.1 to 7.9 times the increases. Stimulation of GH secretion by GHRP 6 was independent of the presence of gsp oncogenes, emphasizing the independent nature of cAMP from its effects. These results provide evidence that the GH-stimulating effects of GHRP 6 are achieved by activation of the second messenger system of PI and thus support earlier findings that PKC and Ca2 + play a central role in mediating the effects of GHRP 6 .

A complete copy of all the essays is available from PeptidesOnline. Please contact us for more information.
Protocol

Content and potency: 5 ml x 1 vial at 2000 μg / ml ready to inject subcutaneously
Suggested dosage: 0.1 ml daily for 5 days out of 7 between 18h and 20h

Write a review

Your Name:


Your Review: Note: HTML is not translated!

Rating: Bad           Good

Enter the code in the box below: